The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis

English version České info

Background:
Point-of-care CD4 tests at HIV diagnosis could improve linkage to care in resource-limited settings. Our objective is to evaluate the clinical and economic impact of point-of-care CD4 tests compared to laboratory-based tests in Mozambique.

Methods and Findings:
We use a validated model of HIV testing, linkage, and treatment (CEPAC-International) to examine two strategies of immunological staging in Mozambique: (1) laboratory-based CD4 testing (LAB-CD4) and (2) point-of-care CD4 testing (POC-CD4). Model outcomes include 5-y survival, life expectancy, lifetime costs, and incremental cost-effectiveness ratios (ICERs). Input parameters include linkage to care (LAB-CD4, 34%; POC-CD4, 61%), probability of correctly detecting antiretroviral therapy (ART) eligibility (sensitivity: LAB-CD4, 100%; POC-CD4, 90%) or ART ineligibility (specificity: LAB-CD4, 100%; POC-CD4, 85%), and test cost (LAB-CD4, US$10; POC-CD4, US$24). In sensitivity analyses, we vary POC-CD4-specific parameters, as well as cohort and setting parameters to reflect a range of scenarios in sub-Saharan Africa. We consider ICERs less than three times the per capita gross domestic product in Mozambique (US$570) to be cost-effective, and ICERs less than one times the per capita gross domestic product in Mozambique to be very cost-effective. Projected 5-y survival in HIV-infected persons with LAB-CD4 is 60.9% (95% CI, 60.9%–61.0%), increasing to 65.0% (95% CI, 64.9%–65.1%) with POC-CD4. Discounted life expectancy and per person lifetime costs with LAB-CD4 are 9.6 y (95% CI, 9.6–9.6 y) and US$2,440 (95% CI, US$2,440–US$2,450) and increase with POC-CD4 to 10.3 y (95% CI, 10.3–10.3 y) and US$2,800 (95% CI, US$2,790–US$2,800); the ICER of POC-CD4 compared to LAB-CD4 is US$500/year of life saved (YLS) (95% CI, US$480–US$520/YLS). POC-CD4 improves clinical outcomes and remains near the very cost-effective threshold in sensitivity analyses, even if point-of-care CD4 tests have lower sensitivity/specificity and higher cost than published values. In other resource-limited settings with fewer opportunities to access care, POC-CD4 has a greater impact on clinical outcomes and remains cost-effective compared to LAB-CD4. Limitations of the analysis include the uncertainty around input parameters, which is examined in sensitivity analyses. The potential added benefits due to decreased transmission are excluded; their inclusion would likely further increase the value of POC-CD4 compared to LAB-CD4.

Conclusions:
POC-CD4 at the time of HIV diagnosis could improve survival and be cost-effective compared to LAB-CD4 in Mozambique, if it improves linkage to care. POC-CD4 could have the greatest impact on mortality in settings where resources for HIV testing and linkage are most limited.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis. PLoS Med 11(9): e32767. doi:10.1371/journal.pmed.1001725
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001725

Souhrn

Zdroje

1. Joint United Nations Programme on HIV/AIDS (2012) Together we will end AIDS. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/jc2296_unaids_togetherreport_2012_en.pdf. Accessed 10 June 2014.

2. ScanlonML, VreemanRC (2013) Current strategies for improving access and adherence to antiretroviral therapies in resource-limited settings. HIV AIDS (Auckl) 5: 1–17.

3. ZachariahR, ReidSD, ChailletP, MassaquoiM, SchoutenEJ, et al. (2011) Viewpoint: why do we need a point-of-care CD4 test for low-income countries? Trop Med Intl Health 16: 37–41.

4. JaniIV, PeterTF (2013) How point-of-care testing could drive innovation in global health. N Engl J Med 368: 2319–2324.

5. World Health Organization (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization. Available: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1. Accessed 11 June 2014.

6. Mozambique Ministry of Health (2009) Guia de tratmento antiretrovial e infecções oportunistas no adulto, adolescente e grávida. Maputo: Ministry of Health. Available: http://www.who.int/hiv/pub/guidelines/mozambique_art.pdf. Accessed 11 June 2014.

7. BassettIV, ReganS, ChettyS, GiddyJ, UhlerLM, et al. (2010) Who starts antiretroviral therapy in Durban, South Africa? Not everyone who should. AIDS 24 (Suppl 1)S37–S44.

8. MicekMA, Gimbel-SherrK, BaptistaAJ, MatedianaE, MontoyaP, et al. (2009) Loss to follow-up of adults in public HIV care systems in central Mozambique: identifying obstacles to treatment. J Acquir Immune Defic Syndr 52: 397–405.

9. LarsonBA, BrennanA, McNamaraL, LongL, RosenS, et al. (2010) Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health 15 (Suppl 1)43–47.

10. KranzerK, ZeineckerJ, GinsbergP, OrrellC, KalaweNN, et al. (2010) Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PLoS ONE 5: e13801.

11. KranzerK, GovindasamyD, FordN, JohnstonV, LawnSD (2012) Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review. J Int AIDS Soc 15: 17383.

12. KayigambaFR, BakkerMI, FikseH, MugishaV, AsiimweA, et al. (2012) Patient enrolment into HIV care and treatment within 90 days of HIV diagnosis in eight Rwandan health facilities: a review of facility-based registers. PLoS ONE 7: e36792.

13. RosenS, FoxMP (2011) Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 8: e1001056.

14. JaniIV, SitoeNE, AlfaiER, ChongoPL, QuevedoJI, et al. (2011) Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet 378: 1572–1579.

15. PattenGE, WilkinsonL, ConradieK, IsaakidisP, HarriesAD, et al. (2013) Impact on ART initiation of point-of-care CD4 testing at HIV diagnosis among HIV-positive youth in Khayelitsha, South Africa. J Int AIDS Soc 16: 18518.

16. LarsonBA, SchnippelK, NdibongoB, XuluT, BrennanA, et al. (2012) Rapid point-of-care CD4 testing at mobile HIV testing sites to increase linkage to care: an evaluation of a pilot program in South Africa. J Acquir Immune Defic Syndr 61: e13–e17.

17. FaalM, NaidooN, GlencrossDK, VenterWD, OsihR (2011) Providing immediate CD4 count results at HIV testing improves ART initiation. J Acquir Immune Defic Syndr 58: e54–e59.

18. WynbergE, CookeG, ShroufiA, StevenDR, FordN (2014) Impact of point-of-care CD4 testing on linkage to HIV care: a systematic review. J Int AIDS Soc 17: 18809.

19. GoldieSJ, YazdanpanahY, LosinaE, WeinsteinMC, AnglaretX, et al. (2006) Cost-effectiveness of HIV treatment in resource-poor settings—the case of Côte d'Ivoire. N Engl J Med 355: 1141–1153.

20. WalenskyRP, WolfLL, WoodR, FofanaMO, FreedbergKA, et al. (2009) When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 151: 157–166.

21. WalenskyRP, WoodR, CiaranelloAL, PaltielAD, LorenzanaSB, et al. (2010) Scaling up the 2010 World Health Organization HIV treatment guidelines in resource-limited settings: a model-based analysis. PLoS Med 7: e1000382.

22. BassettIV, GovindasamyD, ErlwangerAS, HyleEP, KranzerK, et al. (2014) Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. PLoS ONE 9: e85197.

23. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors (1996) Cost effectiveness in health and medicine. New York: Oxford University Press.

24. World Health Organization (2001) Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Available: http://whqlibdoc.who.int/publications/2001/924154550x.pdf. Accessed 10 June 2014.

25. World Health Organization (2005) Cost effectiveness and strategic planning (WHO-CHOICE): cost-effectiveness thresholds. Available: http://www.who.int/choice/costs/CER_thresholds/en/index.html. Accessed June 3, 2014.

26. International Monetary Fund (2012) World economic financial surveys: World Economic Outlook Database [database]. Available: http://www.imf.org/external/pubs/ft/weo/2012/02/weodata/index.aspx. Accessed 5 June 2014.

27. HolmesCB, WoodR, BadriM, ZilberS, WangB, et al. (2006) CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 42: 464–469.

28. ScottLE, GalpinJS, GlencrossDK (2003) Multiple method comparison: statistical model using percentage similarity. Cytometry B Clin Cytom 54: 46–53.

29. MessouE, ChaixML, GabillardD, MingaA, LosinaE, et al. (2011) Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. J Acquir Immune Defic Syndr 56: 356–364.

30. AhonkhaiAA, NoubaryF, MunroA, StarkR, WilkeM, et al. (2012) Not all are lost: interrupted laboratory monitoring, early death, and loss to follow-up (LTFU) in a large South African treatment program. PLoS ONE 7: e32993.

31. MillsEJ, FunkA, KantersS, KawumaE, CooperC, et al. (2013) Long-term healthcare interruptions among HIV-positive patients in Uganda. J Acquir Immune Defic Syndr 12: e23–e27.

32. FoxMP, RosenS (2010) Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007–2009: systematic review. Trop Med Int Health 15 (Suppl 1)1–15.

33. ZachariahR, HarriesAD, ManziM, GomaniP, TeckR, et al. (2006) Acceptance of anti-retroviral therapy among patients infected with HIV and tuberculosis in rural Malawi is low and associated with cost of transport. PLoS ONE 1: e121.

34. ZachariahR, Tayler-SmithK, ManziM, MassaquoiM, MwagombaB, et al. (2011) Retention and attrition during the preparation phase and after start of antiretroviral treatment in Thyolo, Malawi, and Kibera, Kenya: implications for programmes? Trans R Soc Trop Med Hyg 105: 421–430.

35. Voss De LimaY, EvansD, Page-ShippL, BarnardA, SanneI, et al. (2013) Linkage to care and treatment for TB and HIV among people newly diagnosed with TB or HIV-associated TB at a large, inner city South African hospital. PLoS ONE 8: e49140.

36. GlencrossDK, CoetzeeLM, FaalM, MasangoM, StevensWS, et al. (2012) Performance evaluation of the Pima point-of-care CD4 analyser using capillary blood sampling in field tests in South Africa. J Int AIDS Soc 15: 3.

37. SukapiromK, OnlamoonN, ThepthaiC, PolsrilaK, TassaneetrithepB, et al. (2011) Performance evaluation of the Alere PIMA CD4 test for monitoring HIV-infected individuals in resource-constrained settings. J Acquir Immune Defic Syndr 58: 141–147.

38. JaniIV, SitoeNE, ChongoPL, AlfaiER, QuevedoJI, et al. (2011) Accurate CD4 T-cell enumeration and antiretroviral drug toxicity monitoring in primary healthcare clinics using point-of-care testing. AIDS 25: 807–812.

39. Jani IV, Sitoe N, Quevedo J, Lehe J, Peter T (2011) Cost-comparison of point-of-care and laboratory CD4 testing in resource-limited settings [abstract]. 6th IAS Conference on HIV Pathogenesis and Treatment; 17–20 July 2011; Rome, Italy. Available: http://www.iasociety.org/Abstracts/A200743694.aspx. Accessed 2 June 2014.

40. LarsonB, SchnippelK, NdibongoB, LongL, FoxMP, et al. (2012) How to estimate the cost of point-of-care CD4 testing in program settings: an example using the Alere Pima Analyzer in South Africa. PLoS ONE 7: e35444.

41. TuboiSH, BrinkhofMW, EggerM, StoneRA, BraitsteinP, et al. (2007) Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the Antiretroviral Therapy in Low-Income Countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr 45: 52–59.

42. MessouE, AnglaretX, DuvignacJ, Konan-N'driE, KomenaE, et al. (2010) Antiretroviral treatment changes in adults from Côte d'Ivoire: the roles of tuberculosis and pregnancy. AIDS 24: 93–99.

43. BrinkhofMW, Pujades-RodriguezM, EggerM (2009) Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS ONE 4: e5790.

44. MessouE, KouakouM, GabillardD, GouesseP, KoneM, et al. (2011) Medication possession ratio: predicting and decreasing loss to follow-up in antiretroviral treatment programs in Côte d'Ivoire. J Acquir Immune Defic Syndr 57 (Suppl 1)S34–S39.

45. ChiBH, YiannoutsosCT, WestfallAO, NewmanJE, ZhouJ, et al. (2011) Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med 8: e1001111.

46. Centers for Diseases Control and Prevention, ICF Macro (2011) The cost of comprehensive HIV treatment in Mozambique. Report of a cost study of HIV treatment programs in Mozambique. Atlanta (Georgia): Centers for Diseases Control and Prevention.

47. LarsonBA, BiiM, Henly-ThomasS, McCoyK, SaweF, et al. (2013) ART treatment costs and retention in care in Kenya: a cohort study in three rural outpatient clinics. J Int AIDS Soc 16: 18026.

48. MenziesNA, BerrutiAA, BerzonR, FillerS, FerrisR, et al. (2011) The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS 25: 1753–1760.

49. AliyuHB, ChukuNN, Kola-JebutuA, AbubakarZ, TorpeyK, et al. (2012) What is the cost of providing outpatient HIV counseling and testing and antiretroviral therapy services in selected public health facilities in Nigeria? J Acquir Immune Defic Syndr 61: 221–225.

50. Clinton Health Access Initiative (2011) Antiretroviral (ARV) ceiling price list. Available: http://www.clintonhealthaccess.org/files/chai_arv_ceilingPriceList_201105_english.pdf. Accessed 30 May 2014.

51. RosenS, FoxMP, GillCJ (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 4: e298.

52. Mtapuri-ZinyoweraS, ChidemeM, MangwanyaD, MugurungiO, GudukeyaS, et al. (2010) Evaluation of the PIMA point-of-care CD4 analyzer in VCT clinics in Zimbabwe. J Acquir Immune Defic Syndr 55: 1–7.

53. DiawPA, DaneauG, ColyAA, NdiayeBP, WadeD, et al. (2011) Multisite evaluation of a point-of-care instrument for CD4(+) T-cell enumeration using venous and finger-prick blood: the PIMA CD4. J Acquir Immune Defic Syndr 58: e103–e111.

54. van Schaik N, Kranzer K, Myer L, Radithlhalo E, Thebus E, et al.. (2011) Field validation of the PIMA™ Analyzer in a mobile clinic setting in South Africa [abstract]. 18th Conference on Retroviruses and Opportunistic Infections; 27 February–2 March 2011; Boston, Massachusetts, US.

55. ManabeYC, WangY, ElbireerA, AuerbachB, CastelnuovoB (2012) Evaluation of portable point-of-care CD4 counter with high sensitivity for detecting patients eligible for antiretroviral therapy. PLoS ONE 7: e34319.

56. MnyaniCN, McIntyreJA, MyerL (2012) The reliability of point-of-care CD4 testing in identifying HIV-infected pregnant women eligible for antiretroviral therapy. J Acquir Immune Defic Syndr 60: 260–264.

57. World Health Organization (2008) Choosing interventions that are cost effective (WHO-CHOICE): country-specific unit costs. Available: http://www.who.int/choice/country/country_specific/en/index.html. Accessed 29 May 2014.

58. Finney DJ (1971) Statistical method in biological assay. London: Griffin.

59. PolskyD, GlickHA, WillkeR, SchulmanK (1997) Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ 6: 243–252.

60. Republic of Mozambique National AIDS Council, Conselho Nacional de Combate ao HIV/SIDA (2012) GARPR (global AIDS response progress report): for the period 2010–2011. Available: http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/ce_MZ_Narrative_Report[1].pdf. Accessed 13 May 2014.

61. Joint United Nations Programme on HIV/AIDS (2013) Mozambique. Available: http://www.unaids.org/en/Regionscountries/Countries/Mozambique/. Accessed 2 August 2013.

62. World Health Organization (2011) Countries: Mozambique. Available: http://www.who.int/countries/moz/en/. Accessed 20 January 2014.

63. StinnettAA, MullahyJ (1998) Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 18: S68–S80.

64. LarsonBA, SchnippelK, BrennanA, LongL, XuluT, et al. (2013) Same-day CD4 testing to improve uptake of HIV care and treatment in South Africa: point-of-care is not enough. AIDS Res Treat 2013: 941493.

65. van RooyenH, BarnabasRV, BaetenJM, PhakathiZ, JosephP, et al. (2013) High HIV testing uptake and linkage to care in a novel program of home-based HIV counseling and testing with facilitated referral in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr 64: e1–e8.

66. GovindasamyD, KranzerK, van SchaikN, NoubaryF, WoodR, et al. (2013) Linkage to HIV, TB and non-communicable disease care from a mobile testing unit in Cape Town, South Africa. PLoS ONE 8: e80017.

67. SiednerMJ, HabererJE, BwanaMB, WareNC, BangsbergDR (2012) High acceptability for cell phone text messages to improve communication of laboratory results with HIV-infected patients in rural Uganda: a cross-sectional survey study. BMC Med Inform Decis Mak 12: 56.

68. BassettIV, GiddyJ, ChaissonCE, RossD, BogartLM, et al. (2013) A randomized trial to optimize HIV/TB care in South Africa: design of the Sizanani trial. BMC Infect Dis 13: 390.

69. NsigayeR, WringeA, RouraM, KalluvyaS, UrassaM, et al. (2009) From HIV diagnosis to treatment: evaluation of a referral system to promote and monitor access to antiretroviral therapy in rural Tanzania. J Int AIDS Soc 12: 31.

70. HatcherAM, TuranJM, LeslieHH, KanyaLW, KwenaZ, et al. (2012) Predictors of linkage to care following community-based HIV counseling and testing in rural Kenya. AIDS Behav 16: 1295–1307.

71. BemelmansM, van den AkkerT, FordN, PhilipsM, ZachariahR, et al. (2010) Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care. Trop Med Int Health 15: 1413–1420.

72. EstillJ, EggerM, BlaserN, VizcayaLS, GaroneD, et al. (2013) Cost-effectiveness of point-of-care viral load monitoring of ART in resource-limited settings: mathematical modelling study. AIDS 27: 1483–1492.

73. CohenMS, ChenYQ, McCauleyM, GambleT, HosseinipourMC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493–505.